{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:14:21Z","timestamp":1792066461441,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/01357-8)."],"award-info":[{"award-number":["2016\/01357-8)."]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Mol and Cell Biol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Psoriasis is a chronic inflammatory disease dependent upon a complex interaction between genetic predisposition and immunological factors. It is characterized by skin lesions throughout the body, causing great morbidity and affecting life quality. The present study aimed to evaluate the protein and mRNA expression of heparanase-1 (HPSE), heparanase-2 (HPSE2), syndecan-1 (SYND1), metalloproteinases (MMP2, MMP9), and tissue inhibitor metalloproteinases 2 (TIMP2) in skin samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From each psoriasis patient, two samples were collected, one sample from a psoriasis plaque (<jats:italic>n<\/jats:italic>\u2009=\u200923) and the other sample from non-affected skin (<jats:italic>n<\/jats:italic>\u2009=\u200923), as well as tissue collected by blepharoplasty from control individuals (<jats:italic>n<\/jats:italic>\u2009=\u200918). Protein expression was investigated by immunohistochemistry, followed by digital quantification. Quantitative RT-PCR obtained mRNA expression. Statistical analyses were done, and <jats:italic>p<\/jats:italic> values &lt;\u20090.05 were considered significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A significant increase in protein and mRNA expression was observed in both heparanases (HPSE and HPSE2), and higher protein levels of MMP9 and TIMP2 were observed in the psoriasis plaque compared to the non-affected skin. The data point to a probable activation of MMP2 by TIMP2. Moreover, there was a significant increase in HPSE2, SYND1, MMP9, and TIMP2 in non-affected skin samples from patients with psoriasis than in the control sample (tissue obtained by individuals who do not have psoriasis).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results show a possible correlation between the characteristic inflammatory process and alterations in the expression of the extracellular matrix in psoriasis. The increased expression of HPSE2, SYND1, MMP9, and TIMP2, even in the absence of psoriatic plaque, indicates that these molecules may be involved with extracellular matrix changes in the initial alterations the psoriatic process and may be candidates for the development of target treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12860-021-00395-1","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T10:04:04Z","timestamp":1635501844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Extracellular matrix alterations in the skin of patients affected by psoriasis"],"prefix":"10.1186","volume":"22","author":[{"given":"Mariana Fatima Muaccad Gama","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se Rachell","family":"Theodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos D\u2019. Apparecida Santos Machad","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza Keiko Matsuka","family":"Oyafuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4001-1663","authenticated-orcid":false,"given":"Maria Aparecida Silva","family":"Pinhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"issue":"19","key":"395_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"395_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. https:\/\/doi.org\/10.3389\/fimmu.2018.00579.","journal-title":"Front Immunol"},{"issue":"1","key":"395_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. https:\/\/doi.org\/10.1186\/s12895-020-00099-7.","journal-title":"BMC Dermatol"},{"issue":"9583","key":"395_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CEM Griffiths","year":"2007","unstructured":"Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):63\u201371.","journal-title":"Lancet"},{"key":"395_CR5","unstructured":"World Healthy Organization. Global reports on psoriasis. 2016. htpp:\/\/apps.who.int\/iris\/bitstream\/10665\/2014417\/1\/9789241565189_eng.pdf?ua=1."},{"issue":"1","key":"395_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12895-018-0079-8","volume":"18","author":"CI Wootton","year":"2018","unstructured":"Wootton CI, Bell S, Philavanh A, Phommachack K, Soukavong M, Kidoikhammouan S, et al. Assessing skin disease and associated health-related quality of life in a rural Lao community. BMC Dermatol. 2018;18(1):11. https:\/\/doi.org\/10.1186\/s12895-018-0079-8.","journal-title":"BMC Dermatol"},{"issue":"3","key":"395_CR7","first-page":"1","volume":"22","author":"MN Nicholas","year":"2017","unstructured":"Nicholas MN, Gooderham M. Psoriasis, depression, and suicidality. Skin Therapy Lett. 2017;22(3):1\u20134.","journal-title":"Skin Therapy Lett"},{"key":"395_CR8","doi-asserted-by":"publisher","first-page":"e12627","DOI":"10.1111\/dth.12627","volume":"31","author":"K Damevska","year":"2018","unstructured":"Damevska K, Fran\u00e7a K, Lotti T, Nikolovska S, Pollozhani N. Complementary and integrative therapies for psoriasis: Looking forward. Dermatol Ther. 2018;31:e12627.","journal-title":"Dermatol Ther"},{"issue":"4","key":"395_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1067\/mjd.2002.122755","volume":"47","author":"SC Weiss","year":"2002","unstructured":"Weiss SC, Kimbalt AB, Liewehr DJ, Blauvelt A, Turner LM, Emanuel JE. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47(4):512\u20138. https:\/\/doi.org\/10.1067\/mjd.2002.122755.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"395_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312. https:\/\/doi.org\/10.1111\/jdv.13854.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"395_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ijd.13604","volume":"56","author":"R Romini","year":"2017","unstructured":"Romini R, Amone M, Menter A, Miot HA. Prevalence of psoriasis in Brazil, a geographical survey. Int J Dermatol. 2017;56(8):167\u20138. https:\/\/doi.org\/10.1111\/ijd.13604.","journal-title":"Int J Dermatol"},{"issue":"1","key":"395_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10067-016-3460-1","volume":"36","author":"YY Leung","year":"2017","unstructured":"Leung YY, Fong W, Lui NL, Thumboo J. Effect of ethnicity on disease activity and physical function in psoriatic arthritis in a multiethnic Asian population. Clin Rheumatol. 2017;36(1):125\u201331. https:\/\/doi.org\/10.1007\/s10067-016-3460-1.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"395_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Invest Dermatol"},{"issue":"18","key":"395_CR14","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.3390\/ijms20184347","volume":"20","author":"K Kamiya","year":"2019","unstructured":"Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. https:\/\/doi.org\/10.3390\/ijms20184347.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"395_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","volume":"17","author":"IM Bronckers","year":"2015","unstructured":"Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373\u201384. https:\/\/doi.org\/10.1007\/s40272-015-0137-1.","journal-title":"Paediatr Drugs"},{"issue":"12","key":"395_CR16","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1001\/archderm.143.12.1559","volume":"143","author":"C Huerta","year":"2007","unstructured":"Huerta C, Rivero E, Rodr\u00edguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559\u201365. https:\/\/doi.org\/10.1001\/archderm.143.12.1559.","journal-title":"Arch Dermatol"},{"issue":"4","key":"395_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/jid.2009.391","volume":"130","author":"PI Spuls","year":"2010","unstructured":"Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?. Quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933\u201343. https:\/\/doi.org\/10.1038\/jid.2009.391.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"395_CR18","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278\u201385.","journal-title":"Can Fam Physician"},{"issue":"9997","key":"395_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7.","journal-title":"Lancet"},{"issue":"1","key":"395_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12875-016-0544-6","volume":"17","author":"AG Wade","year":"2016","unstructured":"Wade AG, Crawford GM, Young D, Leman J, Pumford N. Severity and management of psoriasis within primary care. BMC Fam Pract. 2016;17(1):145. https:\/\/doi.org\/10.1186\/s12875-016-0544-6.","journal-title":"BMC Fam Pract"},{"issue":"6","key":"395_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"395_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","volume":"28","author":"M Abrouk","year":"2017","unstructured":"Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017;28(6):488\u201391. https:\/\/doi.org\/10.1080\/09546634.2016.1278198.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"395_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000083509","volume":"210","author":"J Schimitt","year":"2005","unstructured":"Schimitt J, Wozel G. The psoriasis area severity index is adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194\u20139. https:\/\/doi.org\/10.1159\/000083509.","journal-title":"Dermatology"},{"key":"395_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fcell.2019.00068","volume":"7","author":"O Bhattacharjee","year":"2019","unstructured":"Bhattacharjee O, Ayyangar U, Kurbet AS, Ashok D, Raghavan S. Unraveling the ECM-immune cell crosstalk in skin diseases. Front Cell Dev Biol. 2019;7:68. https:\/\/doi.org\/10.3389\/fcell.2019.00068.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"395_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2014.01.068","volume":"540","author":"A Mezentsev","year":"2014","unstructured":"Mezentsev A, Nikolaev A, Bruskin S. Matrix metalloproteinases and their role in psoriasis. Gene. 2014;540(1):1\u201310. https:\/\/doi.org\/10.1016\/j.gene.2014.01.068.","journal-title":"Gene"},{"issue":"6","key":"395_CR26","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.4049\/jimmunol.1800104","volume":"201","author":"AK Jaiswal","year":"2018","unstructured":"Jaiswal AK, Sadasivam M, Archer NK, Miller RJ, Dillen CA, Ravipati A, et al. Syndecan-1 regulates Psoriasiform dermatitis by controlling homeostasis of IL-17-producing \u03b3\u03b4 T cells. J Immunol. 2018;201(6):1651\u201361. https:\/\/doi.org\/10.4049\/jimmunol.1800104.","journal-title":"J Immunol"},{"issue":"9","key":"395_CR27","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1096\/fj.00-0895fje","volume":"15","author":"M Elkin","year":"2001","unstructured":"Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001;15(9):1661\u20133. https:\/\/doi.org\/10.1096\/fj.00-0895fje.","journal-title":"FASEB J"},{"issue":"9","key":"395_CR28","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1182\/blood-2005-08-3301","volume":"107","author":"E Edovitsky","year":"2006","unstructured":"Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M. Role of endothelial heparanase in delayed-type hypersensitivity. Blood. 2006;107(9):3609\u201316. https:\/\/doi.org\/10.1182\/blood-2005-08-3301.","journal-title":"Blood"},{"issue":"9","key":"395_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fonc.2019.00331","volume":"29","author":"AJ Mayfosh","year":"2019","unstructured":"Mayfosh AJ, Baschuk N, Hulett MD. Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression. Front Oncol. 2019;29(9):331.","journal-title":"Front Oncol"},{"issue":"12","key":"395_CR30","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00018-013-1496-9","volume":"71","author":"I Lerner","year":"2014","unstructured":"Lerner I, Zcharia E, Neuman T, Hermano E, Rubinstein AM, Vlodavsky I, et al. Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasis form skin inflammation in mice. Cell Mol Life Sci. 2014;71(12):2347\u201357. https:\/\/doi.org\/10.1007\/s00018-013-1496-9.","journal-title":"Cell Mol Life Sci"},{"issue":"2 suppl 1","key":"395_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1590\/abd1806-4841.2019940211","volume":"94","author":"M Arnone","year":"2019","unstructured":"Arnone M, Takahashi MDF, Carvalho AVE, Bernardo WM, Bressan AL, Ramos AMC, et al. Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 suppl 1):76\u2013107. https:\/\/doi.org\/10.1590\/abd1806-4841.2019940211.","journal-title":"An Bras Dermatol"},{"issue":"5","key":"395_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1590\/S1807-59322006000500008","volume":"61","author":"LL Matos","year":"2006","unstructured":"Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozi VL, Pinhal MAS. Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics. 2006;61(5):417\u201324. https:\/\/doi.org\/10.1590\/S1807-59322006000500008.","journal-title":"Clinics"},{"issue":"9","key":"395_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nri1918","volume":"6","author":"CR Parish","year":"2006","unstructured":"Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol. 2006;6(9):633\u201343. https:\/\/doi.org\/10.1038\/nri1918.","journal-title":"Nat Rev Immunol"},{"issue":"7139","key":"395_CR34","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/nature05817","volume":"446","author":"JR Bishop","year":"2007","unstructured":"Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446(7139):1030\u20137. https:\/\/doi.org\/10.1038\/nature05817.","journal-title":"Nature"},{"issue":"48","key":"395_CR35","doi-asserted-by":"publisher","first-page":"E7808","DOI":"10.1073\/pnas.1611380113","volume":"113","author":"L Gutter-Kapon","year":"2016","unstructured":"Gutter-Kapon L, Alishekevitz D, Shaked Y, Li JP, Aronheim A, Ilan N, et al. Heparanase is required for activation and function of macrophages. Proc Natl Acad Sci U S A. 2016;113(48):E7808\u201317. https:\/\/doi.org\/10.1073\/pnas.1611380113.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"395_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/febs.13932","volume":"284","author":"RD Sanderson","year":"2017","unstructured":"Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J. 2017;284(1):42\u201355. https:\/\/doi.org\/10.1111\/febs.13932.","journal-title":"FEBS J"},{"key":"395_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drup.2016.10.001","volume":"29","author":"I Vlodavsky","year":"2016","unstructured":"Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, et al. Heparanase: from basic research to therapeutic applications in cancer and inflammation. Drug Resist Updat. 2016;29:54\u201375. https:\/\/doi.org\/10.1016\/j.drup.2016.10.001.","journal-title":"Drug Resist Updat"},{"key":"395_CR38","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.isci.2019.04.034","volume":"15","author":"CD Mohan","year":"2019","unstructured":"Mohan CD, Hari S, Preetham HD, Rangappa S, Barash U, Ilan N, et al. Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds. iScience. 2019;15:360\u201390.","journal-title":"iScience"},{"issue":"10","key":"395_CR39","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1111\/febs.12168","volume":"280","author":"VC Ramani","year":"2013","unstructured":"Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, et al. The heparanase\/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013;280(10):2294\u2013306. https:\/\/doi.org\/10.1111\/febs.12168.","journal-title":"FEBS J"},{"issue":"36","key":"395_CR40","doi-asserted-by":"publisher","first-page":"28010","DOI":"10.1074\/jbc.M110.116384","volume":"285","author":"F Levy-Adam","year":"2010","unstructured":"Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, et al. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem. 2010;285(36):28010\u20139. https:\/\/doi.org\/10.1074\/jbc.M110.116384.","journal-title":"J Biol Chem"},{"issue":"12","key":"395_CR41","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/blood-2009-07-234757","volume":"115","author":"A Purushothaman","year":"2010","unstructured":"Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood. 2010;115(12):2449\u201357. https:\/\/doi.org\/10.1182\/blood-2009-07-234757.","journal-title":"Blood"},{"issue":"9","key":"395_CR42","first-page":"1254","volume":"47","author":"NL Starodubtseva","year":"2011","unstructured":"Starodubtseva NL, Sobolev VV, Soboleva AG, Nikolaev AA, Bruskin SA. Expression of genes for metalloproteinases (MMP-1, MMP-2, MMP-9, and MMP-12) associated with psoriasis. Genetika. 2011;47(9):1254\u201361.","journal-title":"Genetika"},{"issue":"7","key":"395_CR43","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/08820139.2018.1489831","volume":"47","author":"LM Amezcua-Guerra","year":"2018","unstructured":"Amezcua-Guerra LM, Bojalil R, Espinoza-Hernandez J, Vega-Memije ME, Lacy-Niebla RM, Ortega-Springall F, et al. Serum of patients with psoriasis modulates the production of MMP-9 and TIMP-1 in cells of Monocytic lineage. Immunol Investig. 2018;47(7):725\u201334. https:\/\/doi.org\/10.1080\/08820139.2018.1489831.","journal-title":"Immunol Investig"},{"issue":"6","key":"395_CR44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00403-012-1251-3","volume":"304","author":"E Buommino","year":"2012","unstructured":"Buommino E, De Filippis A, Gaudiello F, Balato A, Balato N, Tufano MA, et al. Modification of osteopontin and MMP9 levels in patients with psoriasis on anti-TNF-\u03b1 therapy. Arch Dermatol Res. 2012;304(6):481\u20135. https:\/\/doi.org\/10.1007\/s00403-012-1251-3.","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"395_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2340\/00015555-1286","volume":"92","author":"U Lindqvist","year":"2012","unstructured":"Lindqvist U, Phil-Lundin I, Engstr\u00f6m-Laurent A. Dermal distribution of hyaluronan in psoriatic arthritis; coexistence of CD44, MMP3 and MMP9. Acta Derm Venereol. 2012;92(4):372\u20137. https:\/\/doi.org\/10.2340\/00015555-1286.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"395_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.matbio.2009.01.001","volume":"28","author":"TR Kyriakides","year":"2009","unstructured":"Kyriakides TR, Wulsin D, Skokos EA, Fleckman P, Pirrone A, Shipley JM, et al. Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol. 2009;28(2):65\u201373.","journal-title":"Matrix Biol"},{"issue":"22","key":"395_CR47","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.3390\/ijms20225617","volume":"20","author":"M Diani","year":"2019","unstructured":"Diani M, Perego S, Sansoni V, Bertino L, Gomarasca M, Faraldi M, et al. Differences in Osteoimmunological biomarkers predictive of psoriatic arthritis among a large Italian cohort of psoriatic patients. Int J Mol Sci. 2019;20(22):5617. https:\/\/doi.org\/10.3390\/ijms20225617.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"395_CR48","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1046\/j.1523-1747.2000.00138.x","volume":"115","author":"R Fleischmajer","year":"2000","unstructured":"Fleischmajer R, Kuroda K, Hazan R, Gordon RE, Lebwohl MG, Sapadin NA, et al. Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP2 and its inhibitor TIMP-2. J Invest Dermatol. 2000;115(5):771\u20137. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00138.x.","journal-title":"J Invest Dermatol"},{"key":"395_CR49","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2147\/TCRM.S113769","volume":"12","author":"EK G\u0142a\u017cewska","year":"2016","unstructured":"G\u0142a\u017cewska EK, Niczyporuk M, Lawicki S, Szmitkowski M, Zajkowska M, Bedkowska GE, et al. Therapy of psoriasis with narrowband ultraviolet-B light influences plasma concentrations of MMP2 and TIMP-2 in patients. Ther Clin Risk Manag. 2016;12:1579\u201385. https:\/\/doi.org\/10.2147\/TCRM.S113769.","journal-title":"Ther Clin Risk Manag"},{"issue":"19","key":"395_CR50","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1242\/jcs.00063","volume":"115","author":"AH Baker","year":"2002","unstructured":"Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115(19):3719\u201327. https:\/\/doi.org\/10.1242\/jcs.00063.","journal-title":"J Cell Sci"},{"issue":"5","key":"395_CR51","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ijc.20009","volume":"109","author":"G Giannelli","year":"2004","unstructured":"Giannelli G, Erriquez R, Fransvea E, Daniele A, Tirerotoli P, Schittulli F, et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer. 2004;109(5):782\u20135. https:\/\/doi.org\/10.1002\/ijc.20009.","journal-title":"Int J Cancer"},{"issue":"1","key":"395_CR52","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1749-6632.1999.tb07677.x","volume":"878","author":"L Blavier","year":"1999","unstructured":"Blavier L, Henriet P, Imren S. deClerck YA. Tissue inhibitors of matrix metalloproteinases in cancer. Ann N Y Acad Sci. 1999;878(1):108\u201319. https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb07677.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20132","key":"395_CR53","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0167-4838(99)00279-4","volume":"1477","author":"K Brew","year":"2000","unstructured":"Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477(1\u20132):267\u201383. https:\/\/doi.org\/10.1016\/S0167-4838(99)00279-4.","journal-title":"Biochim Biophys Acta"},{"issue":"22","key":"395_CR54","doi-asserted-by":"publisher","first-page":"13453","DOI":"10.1074\/jbc.270.22.13453","volume":"270","author":"ML Corcoran","year":"1995","unstructured":"Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem. 1995;270(22):13453\u20139. https:\/\/doi.org\/10.1074\/jbc.270.22.13453.","journal-title":"J Biol Chem"},{"issue":"8","key":"395_CR55","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","volume":"92","author":"R Visse","year":"2003","unstructured":"Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ Res. 2003;92(8):827\u201339. https:\/\/doi.org\/10.1161\/01.RES.0000070112.80711.3D.","journal-title":"Circ Res"}],"container-title":["BMC Molecular and Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12860-021-00395-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12860-021-00395-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12860-021-00395-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T10:04:31Z","timestamp":1635501871000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmolcellbiol.biomedcentral.com\/articles\/10.1186\/s12860-021-00395-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1186\/s12860-021-00395-1","relation":{},"ISSN":["2661-8850"],"issn-type":[{"value":"2661-8850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was approved by a National Ethics Committee Pataforma Brasil (), Certificate of Presentation of Ethical Appreciation (CAAE 17345114.2.0000.0082). Ethics Approval Process Number 676.610. The consent form of the study participants was obtained by written declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}